U.S. Stock News

Comcast (CMCSA) has wrapped up FY 2025 with fourth quarter revenue of US$32.3b and basic EPS of US$0.60, alongside trailing twelve month revenue of US$123.7b and EPS of US$5.39. Over the last six reported quarters, revenue has ranged from US$29.9b to US$32.3b, while quarterly EPS has moved between US$0.60 and US$2.99. This gives investors a clear view of how earnings per share translate off a large and relatively steady top line base. With a trailing net margin of 16.2% against 13.1% a year...

Minerals Technologies (MTX) has wrapped up FY 2025 with fourth quarter revenue of US$519.5 million and EPS of US$1.19, set against a 12‑month backdrop where trailing revenue sat at about US$2.1 billion and EPS was slightly negative at US$0.59. Over recent quarters the company has seen quarterly revenue move from US$518.1 million in Q4 2024 to US$528.9 million in Q2 2025 and US$532.4 million in Q3 2025 before landing at US$519.5 million in Q4 2025. Over the same period, EPS shifted from...

If you are wondering whether Popular's share price still reflects good value or if most of the opportunity is already priced in, this article walks through the key signals you can use to form your own view. Popular's shares last closed at US$133.53, with returns of 9.5% over the past 7 days, 7.2% over 30 days, 6.0% year to date, 33.3% over 1 year, 106.6% over 3 years, and 149.1% over 5 years. These figures raise fair questions about what is now built into expectations and perceived...

AI-driven trading interest puts Gorilla Technology Group (GRRR) in focus Recent AI model outputs flagging positive near and mid-term sentiment for Gorilla Technology Group (GRRR) have pulled the stock into the spotlight, as institutional-style trading frameworks emphasize risk-reward trade setups instead of new fundamental catalysts. See our latest analysis for Gorilla Technology Group. Gorilla Technology Group’s share price has been volatile, with a 29.30% 1 month share price return and a...

ResMed Q2 2026 earnings in focus ResMed (RMD) has just posted its Q2 2026 earnings, with revenue of about US$1.4b and basic EPS of US$2.69 setting the tone for the latest quarter. The company reported revenue of US$1,282.1m in Q2 2025 and US$1,422.8m in Q2 2026, while basic EPS over the same quarters moved from US$2.35 to US$2.69. This gives investors a clearer view of both top line and per share performance. With trailing net profit margins at 27.5% and earnings growth already in focus, this...

When you see that almost half of the companies in the Energy Services industry in the United States have price-to-sales...

WF International (NASDAQ:WXM) has had a rough three months with its share price down 83%. However, stock prices are...

Key Insights Significantly high institutional ownership implies Prime Medicine's stock price is sensitive to their...

Investors who take an interest in Worthington Steel, Inc. ( NYSE:WS ) should definitely note that the Independent...

Anyone interested in EverCommerce Inc. ( NASDAQ:EVCM ) should probably be aware that the Founder, Eric Remer, recently...

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Pop Culture Group Co., Ltd ( NASDAQ:CPOP ) is a stock...

With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Chemicals industry in the United States, you...

GDS Holdings Limited ( NASDAQ:GDS ) shareholders have had their patience rewarded with a 28% share price jump in the...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Investors in Chain Bridge Bancorp, Inc. ( NYSE:CBNA ) had a good week, as its shares rose 5.8% to close at US$35.24...

Lazard (NYSE:LAZ) has appointed Tracy Farr as its new Chief Financial Officer. The leadership change is intended to support the firm's long term growth and operational efficiency plans. Farr brings extensive internal experience at Lazard to the CFO role. Lazard, traded on the NYSE under the ticker NYSE:LAZ, recently closed at $53.72. The stock has seen a 4.6% return over the past week and 10.6% over the past month, with a 62.1% return over five years. In that context, a CFO transition can...

With the business potentially at an important milestone, we thought we'd take a closer look at NEXGEL, Inc.'s...

Caterpillar (CAT) just turned in its FY 2025 scorecard with fourth quarter revenue of US$19.1b and basic EPS of US$5.15, alongside net income of US$2.4b. Over recent quarters, the company has seen revenue move from US$16.0b in Q3 2024 to US$17.6b in Q3 2025 and then US$19.1b in Q4 2025. Basic EPS shifted from US$5.09 to US$4.91 and then US$5.15 over the same stretch, setting up a results season where investors are weighing solid top line scale against a backdrop of compressed net margins and...

Central Securities (CET) has been in focus after reporting 9.3% year over year growth in net assets and higher net assets per share, alongside its stock touching an all time high of US$52.46. See our latest analysis for Central Securities. The latest share price of US$52.10 sits just below its recent all time high, and the 1 year total shareholder return of 15.44% and 5 year total shareholder return of 106.06% point to momentum that has built over time rather than fading quickly. If Central...

Readers hoping to buy Princeton Bancorp, Inc. ( NASDAQ:BPRN ) for its dividend will need to make their move shortly, as...

With a price-to-earnings (or "P/E") ratio of 38.8x Vitesse Energy, Inc. ( NYSE:VTS ) may be sending very bearish...

If you are wondering whether BeOne Medicines is attractively priced right now, the key question is how its current share price stacks up against its underlying fundamentals. The stock has returned 0.3% over the last 7 days, 12.0% over 30 days, 9.4% year to date, 51.3% over 1 year and 32.5% over 3 years, while the 5 year return stands at an 8.5% decline. These moves sit against a backdrop of ongoing interest in the pharmaceuticals and biotech space, where investors often react quickly to...

If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline. Recent attention on Olema has centered on its position in the pharmaceuticals and biotech space...

Key Insights Significant control over Cheetah Mobile by public companies implies that the general public has more power...